A cohort study reporting clinical risk factors and individual risk perceptions of prostate cancer: Implications for PSA testing

BJU International

Volumn 111, Issue 3, 2013, Pages 389-395

  Forbat, Liz ^a   Place, Morag ^a   Kelly, Daniel ^b   Hubbard, Gill ^a   Boyd, Kenny ^c   Howie, Kate ^a   Leung, Hing Y ^d  

^a UNIVERSITY OF STIRLING   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

prostate cancer; PSA; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; AWARENESS; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER RISK PERCEPTION; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; HIGH RISK PATIENT; HUMAN; INTERPERSONAL EXPERIENCE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT EDUCATION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SOCIAL NETWORK; SYMPTOM; URINARY SYMPTOM;

AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 84874649053     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11316.x     Document Type: Article

References (28)

1. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-551
2. Xu J, Kibel AS, Hu JJ,. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009 18: 2145-2149
3. Johns LE, Houlston RS,. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003 91: 789-794
4. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT,. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000; 90: 1595-1600
5. Fitzpatrick JM, Kirby RS, Brough CL, Saggerson AL,. Awareness of prostate cancer among patients and the general public: results of an international survey. Prostate Cancer Prostatic Dis 2009; 12: 347-354
6. Fitzpatrick P, Corcoran N, Fitzpatrick JM,. Prostate cancer: how aware is the public? Br J Urol 1998; 82: 43-48
7. Jacobsen PB, Lamonde LA, Honour M, Kash K, Hudson PB, Pow-Sang J., Relation of family history of prostate cancer to perceived vulnerability and screening behavior. Psychooncology 2004; 13: 80-85
8. Bratt O, Damber JE, Emanuelsson M, et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000 36: 235-241
9. Bloom JR, Stewart SL, Oakley-Girvans I, Banks PJ, Chang SB., Family history, perceived risk, and prostate cancer screening among African American men. Cancer Epidemiol Biomarkers Prev 2006 15: 2167-2173
10. Montgomery GH, Erblich J, DiLorenzo T, Bovbjerg DH., Family and friends with disease: their impact on perceived risk. Prev Med 2003; 37: 242-249
11. de Nooijer J, Lechner L, de, Vries H., A qualitative study on detecting cancer symptoms and seeking medical help; an application of Andersen's model of total patient delay. Patient Educ Couns 2001 42: 145-157
12. Smith LK, Pope C, Botha JL,. Patients' help-seeking experiences and delay in cancer presentation: a qualitative synthesis. Lancet 2005; 366: 825-831
13. Andriole GL., Editorial: screening for prostate cancer. BMJ 2010; 341: c4538
14. Stavridis S, Saidi S, Lekovski LJ, Dohcev S, Spasovski G,. Screening for prostate cancer: a controversy or fact. Hippokratia 2010 14: 170-175
15. Stark JR, Mucci L, Rothman KJ, Adami HO,. Screening for prostate cancer remains controversial. BMJ 2009; 339: b3601
16. Barry MJ., Screening for prostate cancer-the controversy that refuses to die. N Engl J Med 2009; 360: 1351-1354
17. Bangmaa CH, van Schaikb RH, Blijenbergb BG, Roobola MJ, Liljac H, Stenmand U., On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Eur J Cancer 2011; 46: 3109-3119
18. Creswell JW, Plano Clark VL., Designing and Conducting Mixed Methods Research. London: Sage, 2006
19. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009 103: 464-469
20. Macleod U, Mitchell ED, Burgess C, Macdonald S, Ramirez AJ,. Risk factors for delayed presentation and referral of symptomatic cancer: evidence for common cancers. Br J Cancer 2009 101: 92-101
21. Young JM, Muscatello DJ, Ward JE,. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000 85: 1037-1048
22. Lane JA, Hamdy FC, Martin RM, Neal DE, Donovan JL,. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010; 46: 3095-3101
23. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319
24. Walsh D, Bendel N, Jones R, Hanlon P. Investigating A, 'Glasgow Effect'. Glasgow: Glasgow Centre for Population Health, 2010
25. Alexander AS, Mydin A, Jones SO, et al. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA) >40 ng/ml: prognostic significance of the preradiation PSA nadir. Int J Radiat Oncol Biol Phys 2011; 81: e713-719
26. Schroder FH., Screening for prostate cancer (PC)-an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol 2008 26: 533-541
27. Dobson R., More evidence suggests that PSA testing leads to 'overdiagnosis' of cancer. BMJ 2006; 22: 166
28. Pashayan N, Powles J, Brown C, Duffy SW,. Excess cases of prostate cancer and estimated over diagnosis associated with PSA testing in East Anglia. Br J Cancer 2006; 95: 401-405